Abstract: The present invention concerns affinity matured CRIg variants. In particular, the invention concerns CRIg variants having increased binding affinity to C3b and retaining selective binding to C3b over C3.
Type:
Grant
Filed:
May 6, 2009
Date of Patent:
January 12, 2016
Assignee:
GENENTECH, INC.
Inventors:
Sachdev S. Sidhu, Bing Li, Menno Van Lookeren Campagne, Christian Wiesmann
Abstract: The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.
Type:
Application
Filed:
July 16, 2015
Publication date:
January 7, 2016
Applicant:
Genentech, Inc.
Inventors:
Anthony ESTRADA, Wen Liu, Snahel Patel, Michael Siu
Abstract: Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided.
Type:
Application
Filed:
September 11, 2015
Publication date:
January 7, 2016
Applicant:
GENENTECH, INC.
Inventors:
Natarajan VIJAYASANKARAN, Steven J. MEIER, Sharat VARMA, Yi YANG
Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).
Type:
Application
Filed:
September 22, 2015
Publication date:
January 7, 2016
Applicants:
GENENTECH, INC., AC IMMUNE S.A.
Inventors:
Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
Abstract: Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
Type:
Application
Filed:
March 1, 2013
Publication date:
January 7, 2016
Applicants:
GENENTECH, INC., FORMA TM, LLC
Inventors:
Kenneth W BAIR, Timm R BAUMEISTER, Peter DRAGOVICH, Xiongcai LIU, Snahel PATEL, Po-Wai YUEN, Mark ZAK, Guiling ZHAO, Yamin ZHANG, Xiaozhang ZHENG
Abstract: Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic tests. The [125I] HIP-DOTA label reagent 6 is prepared by an efficient and convenient process.
Type:
Application
Filed:
July 31, 2015
Publication date:
January 7, 2016
Applicant:
GENENTECH, INC.
Inventors:
Charles Andrew Boswell, Leslie A. Khawli, Jan Marik, Simon Williams
Abstract: The invention provides a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.0 to about 6.0, and an optional surfactant, methods for making such a formulation, and methods of using such a formulation.
Type:
Grant
Filed:
October 4, 2013
Date of Patent:
January 5, 2016
Assignee:
Genentech, Inc.
Inventors:
Yatin R. Gokarn, Timothy J. Kamerzell, Megan Li, Mary Cromwell, Hong Liu
Abstract: The present invention relates generally to the inhibition of tumor angiogenesis. In particular, the invention concerns the prevention or treatment of tumor angiogenesis and the suppression of tumor growth in tumors refractory to an anti-vascular endothelial growth factor (VEGF) treatment, using IL-17 antagonists, such as anti-IL-17 antibodies and other antagonists.
Abstract: The invention provides intermediates and processes of preparation thereof useful in the preparation of compounds that can be used as CHK1 inhibitors.
Abstract: The present invention is related to safe and functional antibodies for the therapeutic and diagnostic use in the treatment of an amyloidosis, a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease.
Type:
Grant
Filed:
July 29, 2011
Date of Patent:
December 29, 2015
Assignees:
AC IMMUNE S.A., GENENTECH, INC.
Inventors:
Andrea Pfeifer, Andreas Muhs, Oskar Adolfsson, Ryan J. Watts
Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
Type:
Application
Filed:
May 22, 2014
Publication date:
December 24, 2015
Applicant:
GENENTECH, INC.
Inventors:
Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
Abstract: The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
Type:
Application
Filed:
December 20, 2013
Publication date:
December 24, 2015
Applicant:
Genentech, Inc.
Inventors:
Hazel Joan Dyke, Emanuela Gancia, Lewis J. Gazzard, Simon Charles Goodacre, Joseph P. Lyssikatos, Calum MacLeod, Karen Williams, Huifen Chen
Abstract: Methods of use of compounds of formula (I) for treating cancer: wherein X, Y, X, R3, R5 and R6 are as defined herein.
Type:
Grant
Filed:
April 17, 2014
Date of Patent:
December 22, 2015
Assignee:
Genentech, Inc.
Inventors:
Huifen Chen, Hazel Joan Dyke, Charles Ellwood, Emanuela Gancia, Lewis J. Gazzard, Simon Goodacre, Samuel Kintz, Joseph Lyssikatos, Calum MacLeod, Karen Williams
Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, A, X1, X2, X3, X4, R1, R2, R3a, R3b, R4a and R4b are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
Abstract: The invention provides for methods of decreasing dual leucine zipper kinase (DLK) stability in a neuron, or decreasing or inhibiting the phosphorylation of certain amino acid residues of DLK, comprising administering to a neuron, or portion thereof, an agent which decreases or inhibits the phosphorylation of DLK and decreases the stability of DLK as well as methods for inhibiting or preventing neuronal degeneration in a patient by administering to a patient an agent which inhibits phosphorylation of dual leucine zipper kinase (DLK).
Type:
Application
Filed:
August 28, 2015
Publication date:
December 17, 2015
Applicant:
GENENTECH, INC.
Inventors:
Daisy BUSTOS, Sarah HUNTWORK-RODRIGUEZ, Donald KIRKPATRICK, Joseph Wesley LEWCOCK, Arundhati Sengupta GHOSH